These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 31715653)
1. Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin. Beheshti D Health Econ; 2019 Dec; 28(12):1449-1461. PubMed ID: 31715653 [TBL] [Abstract][Full Text] [Related]
2. A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C. Powell D; Alpert A; Pacula RL Health Aff (Millwood); 2019 Feb; 38(2):287-294. PubMed ID: 30715966 [TBL] [Abstract][Full Text] [Related]
3. The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation. Wolff C; Dowd WN; Ali MM; McClellan C; Meinhofer A; Glos L; Mutter R; Rosenberg M; Schick A Addict Behav; 2020 Jun; 105():106268. PubMed ID: 32036188 [TBL] [Abstract][Full Text] [Related]
4. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195 [TBL] [Abstract][Full Text] [Related]
5. The release of abuse-deterrent OxyContin and adolescent heroin use. DiNardi M Drug Alcohol Depend; 2021 Dec; 229(Pt B):109114. PubMed ID: 34638038 [TBL] [Abstract][Full Text] [Related]
6. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties. Cheng HG; Coplan PM Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755 [TBL] [Abstract][Full Text] [Related]
7. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin. Cicero TJ; Ellis MS JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692 [TBL] [Abstract][Full Text] [Related]
8. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Coplan PM; Kale H; Sandstrom L; Landau C; Chilcoat HD Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1274-82. PubMed ID: 24123484 [TBL] [Abstract][Full Text] [Related]
9. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse. McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858 [TBL] [Abstract][Full Text] [Related]
10. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575 [TBL] [Abstract][Full Text] [Related]
11. Impact of abuse-deterrent OxyContin on prescription opioid utilization. Hwang CS; Chang HY; Alexander GC Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216 [TBL] [Abstract][Full Text] [Related]
12. The impact of OxyContin reformulation at the Sydney Medically Supervised Injecting Centre: Pros and cons. Jauncey M; Livingston M; Salmon AM; Dietze P Int J Drug Policy; 2018 Mar; 53():17-22. PubMed ID: 29268238 [No Abstract] [Full Text] [Related]
13. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder. Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589 [TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical opioid use among oral and intravenous users in Australia: A qualitative comparative study. Dertadian G; Iversen J; Dixon TC; Sotiropoulos K; Maher L Int J Drug Policy; 2017 Mar; 41():51-58. PubMed ID: 28107670 [TBL] [Abstract][Full Text] [Related]
15. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614 [TBL] [Abstract][Full Text] [Related]
16. The misuse and abuse of prescription medications: part 1 current trends. Allread V; Paul S MD Advis; 2014; 7(4):12-20. PubMed ID: 25485815 [TBL] [Abstract][Full Text] [Related]
17. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480 [TBL] [Abstract][Full Text] [Related]
18. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin). Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220 [TBL] [Abstract][Full Text] [Related]
19. Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013. Jones CM; Muhuri PK; Lurie PG Clin J Pain; 2017 May; 33(5):452-461. PubMed ID: 27513641 [TBL] [Abstract][Full Text] [Related]
20. Early OxyContin Marketing Linked To Long-Term Spread Of Infectious Diseases Associated With Injection Drug Use. Dennett JM; Gonsalves GS Health Aff (Millwood); 2023 Aug; 42(8):1081-1090. PubMed ID: 37467441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]